Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 6Phase 1 5Phase 1/2 4Phase 2/3 2Phase 4 1

Status

Completed 9Active not recruiting 9Recruiting 7Withdrawn 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7

Conditions

Multiple Myeloma 7Recurrence 1Neoplasms, Plasma Cell 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 52Fluorouracil 52Magnetic Resonance Spectroscopy 50Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 44Leucovorin 39Drug Therapy 39Irinotecan 37Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × carfilzomib × Clear all
NCT05438043 2026-06-05

A Study of Daratumumab

Janssen Research & Development, LLC

Phase 3 Recruiting
500 enrolled
Plasma cell

Multiple Myeloma

NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06158841 2026-06-05

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06615479 2026-06-04

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Recruiting
440 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07555938 2026-05-27

CEVOLUTION

Hoffmann-La Roche

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06413498 2026-05-07

iMMagine-3

Gilead Sciences

Phase 3 Recruiting
450 enrolled
Plasma cell

Multiple Myeloma

NCT07391657 2026-04-30

DURGA-4

AstraZeneca

Phase 3 Recruiting
508 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡